MCID: GST012
MIFTS: 47

Gastroesophageal Junction Adenocarcinoma

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma 11 14
Adenocarcinoma of the Gastroesophageal Junction 71
Adenocarcinoma of Cardioesophageal Junction 11
Adenocarcinoma of Gastroesophageal Junction 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4944
NCIt 49 C9296
UMLS 71 C1332166

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary: Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to esophagus adenocarcinoma and microinvasive gastric cancer, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cetuximab and Gefitinib have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell migration

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)
# Related Disease Score Top Affiliating Genes
1 esophagus adenocarcinoma 30.9 TP53 ERBB2 EGFR
2 microinvasive gastric cancer 30.1 VEGFC TP53 ERBB2
3 gastric adenocarcinoma 30.1 TP53 MET FGFR2 ERBB3 ERBB2
4 papillary carcinoma 29.7 VEGFC MET ERBB2
5 exanthem 29.5 VEGFA PDCD1 MTUS2 MTUS1 ERBB2 EGFR
6 adenocarcinoma 29.5 VEGFD VEGFC VEGFA TP53 MET KDR
7 peripheral nervous system disease 29.4 VEGFA TP53 KDR ERBB2 EGFR CTLA4
8 squamous cell carcinoma 29.2 VEGFC VEGFA TP53 MTUS1 FGFR2 ERBB2
9 gastric cancer 28.4 VEGFD VEGFC VEGFA TP53 MET KDR
10 esophageal cancer 27.9 VEGFD VEGFC VEGFA TP53 PDCD1LG2 PDCD1
11 gastroesophageal adenocarcinoma 27.8 VEGFA TP53 PDCD1LG2 PDCD1 MTUS2 MTUS1
12 breast cancer 27.0 VEGFD VEGFC VEGFA TP53 PDCD1 MTUS1
13 neutropenia 10.7
14 factor vii deficiency 10.4
15 barrett esophagus 10.4
16 mucositis 10.4
17 esophagitis 10.4
18 vulva verrucous carcinoma 10.4 PDCD1 CD274
19 gastroesophageal reflux 10.4
20 rhabdomyosarcoma 2 10.4
21 hypoganglionosis 10.3 ERBB3 ERBB2
22 helicobacter pylori infection 10.3
23 stomatitis 10.3
24 angiokeratoma of mibelli 10.3 KDR FLT1
25 conjunctival vascular disease 10.3 VEGFA KDR
26 peptic esophagitis 10.2
27 acneiform dermatitis 10.2 ERBB3 EGFR
28 testicular lymphoma 10.2 PDCD1LG2 PDCD1 CD274
29 type 1 diabetes mellitus 21 10.2 PDCD1LG2 PDCD1 CD274
30 paronychia 10.2 ERBB3 ERBB2 EGFR
31 malignant dermis tumor 10.2 CTLA4 CD274
32 mucinous lung adenocarcinoma 10.2 ERBB3 EGFR
33 vulvar melanoma 10.2 CTLA4 CD274
34 mucosal melanoma 10.2 PDCD1 CTLA4 CD274
35 malignant skin fibrous histiocytoma 10.2 CTLA4 CD274
36 hair disease 10.2 VEGFA ERBB2 EGFR
37 angiokeratoma circumscriptum 10.2 VEGFA KDR FLT1
38 thymus squamous cell carcinoma 10.2 MTUS2 MTUS1
39 capillary hemangioma 10.2 VEGFA KDR FLT1
40 intussusception 10.2 VEGFA KDR FLT1
41 squamous blepharitis 10.2 ERBB3 EGFR
42 capillary disease 10.2 VEGFA KDR FLT1
43 gray zone lymphoma 10.2 PDCD1LG2 CD274
44 rosacea 10.2 VEGFA KDR FLT1
45 thyroid crisis 10.2 MTUS2 MTUS1
46 ovarian hyperstimulation syndrome 10.2 VEGFA KDR FLT1
47 uveal disease 10.2 VEGFA CTLA4 CD274
48 mismatch repair cancer syndrome 1 10.2
49 diarrhea 10.2
50 interstitial lung disease 10.2

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:



Diseases related to Gastroesophageal Junction Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10 CD274
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10 MET
4 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10 ERBB3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10 EGFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10 FLT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-171 10 FLT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10 CLDN18
12 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10 CLDN18
13 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10 CD274
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10 MET
15 Increased shRNA abundance (Z-score > 2) GR00366-A-187 10 CD274
16 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10 MET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10 CD274
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10 CD274
23 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10 FLT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10 MET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10 MET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10 CLDN18
29 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10 KDR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10 CLDN18
31 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10 ERBB2 ERBB3 KDR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10 CLDN18 ERBB2 MET
33 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10 CLDN18
34 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10 MET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10 CD274 EGFR ERBB2 ERBB3 FLT1 KDR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10 ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10 CLDN18
38 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10 EGFR
39 Increased cell migration GR00055-A-1 9.46 KDR VEGFC
40 Increased cell migration GR00055-A-3 9.46 KDR VEGFC
41 Increased cell viability after pRB stimulation GR00230-A-1 9.26 EGFR ERBB2 ERBB3 MET

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
2 growth/size/body region MP:0005378 10.38 CLDN18 EGFR ERBB2 ERBB3 FGFR2 FLT1
3 neoplasm MP:0002006 10.34 EGFR ERBB2 ERBB3 FGFR2 MET MTUS1
4 normal MP:0002873 10.33 CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
5 nervous system MP:0003631 10.32 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6 cardiovascular system MP:0005385 10.31 CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
7 immune system MP:0005387 10.31 CD274 CLDN18 CTLA4 EGFR ERBB3 FGFR2
8 endocrine/exocrine gland MP:0005379 10.3 CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
9 muscle MP:0005369 10.27 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
10 cellular MP:0005384 10.27 CD274 CLDN18 EGFR ERBB2 ERBB3 FGFR2
11 no phenotypic analysis MP:0003012 10.19 CD274 EGFR FGFR2 KDR MET PDCD1LG2
12 digestive/alimentary MP:0005381 10.19 CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
13 liver/biliary system MP:0005370 10.16 CTLA4 EGFR FGFR2 KDR MET PDCD1
14 embryo MP:0005380 10.16 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
15 respiratory system MP:0005388 10.11 CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
16 craniofacial MP:0005382 10.02 EGFR ERBB2 FGFR2 KDR MET TP53
17 skeleton MP:0005390 10.02 CD274 CLDN18 CTLA4 EGFR ERBB2 FGFR2
18 pigmentation MP:0001186 10 CTLA4 EGFR ERBB3 FGFR2 TP53
19 hematopoietic system MP:0005397 10 CD274 CLDN18 CTLA4 EGFR ERBB2 FGFR2
20 vision/eye MP:0005391 9.91 EGFR FGFR2 FLT1 KDR MET PDCD1
21 mortality/aging MP:0010768 9.89 CD274 CTLA4 EGFR ERBB2 ERBB3 FGFR2
22 integument MP:0010771 9.28 CD274 CTLA4 EGFR ERBB2 ERBB3 FGFR2

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 3 205923-56-4
2
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
3
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
4
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2 135565884
5
Tucatinib Approved, Investigational Phase 2, Phase 3 937263-43-9 51039094
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
8
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
9
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
10
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
13
Rivoceranib Investigational Phase 3 811803-05-1 11315474
14
Bemarituzumab Investigational Phase 3 1952272-74-0
15
Rilotumumab Investigational Phase 3 872514-65-3
16 Protein Kinase Inhibitors Phase 2, Phase 3
17 Antimetabolites Phase 3
18 Analgesics Phase 3
19 Central Nervous System Stimulants Phase 3
20 Antiemetics Phase 3
21 Opiate Alkaloids Phase 3
22 Endothelial Growth Factors Phase 3
23 Trastuzumab biosimilar HLX02 Phase 3
24 Albumin-Bound Paclitaxel Phase 3
25 Antimitotic Agents Phase 3
26 Tubulin Modulators Phase 3
27 Immunoglobulins, Intravenous Phase 3
28 Immunoglobulins Phase 3
29 Antibodies, Monoclonal Phase 3
30 Antibodies Phase 3
31 Pharmaceutical Solutions Phase 3
32 Mitogens Phase 3
33 Immunoglobulin G Phase 3
34 Anti-Bacterial Agents Phase 3
35 Antibiotics, Antitubercular Phase 3
36 Taxane Phase 2, Phase 3 108169
37
Ado-Trastuzumab Emtansine Phase 2, Phase 3
38
Maytansine Phase 2, Phase 3
39
Raltitrexed Approved, Investigational Phase 2 112887-68-0 104758 135400182
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
41
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
42
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
43
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
44
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
45
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
46
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
47
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
48
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
49
Avelumab Approved, Investigational Phase 2 1537032-82-8
50
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7

Interventional clinical trials:

(show top 50) (show all 281)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study Completed NCT02426034 Phase 4 ApatinibTablets
2 A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy Unknown status NCT04342910 Phase 3 camrelizumab;Apatinib Mesylate;Paclitaxel;Irinotecan
3 A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine Unknown status NCT04435652 Phase 2, Phase 3 QL1604;Nab-paclitaxel;Paclitaxel
4 Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ,III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction Unknown status NCT03986385 Phase 3 Apatinib Capecitabine Oxaliplatin;Capecitabine Oxaliplatin
5 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Unknown status NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
6 Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection Unknown status NCT01523015 Phase 2, Phase 3
7 A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Unknown status NCT02409199 Phase 2, Phase 3 Docetaxel;apatinib
8 A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02625623 Phase 3 Avelumab;Irinotecan;Paclitaxel
9 A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy Completed NCT00917384 Phase 3 Placebo
10 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT02370498 Phase 3 paclitaxel
11 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
12 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) Completed NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
13 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
14 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
15 Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer Completed NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
16 Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
17 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
18 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
19 Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy Completed NCT01243398 Phase 3
20 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
21 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
22 A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting NCT03604991 Phase 2, Phase 3 Carboplatin;Paclitaxel
23 An International, Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma After Radical Gastrectomy Recruiting NCT05180734 Phase 3
24 A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06) Recruiting NCT05002127 Phase 2, Phase 3 Evorpacept (ALX148);Trastuzumab;Ramucirumab;Paclitaxel
25 A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Recruiting NCT04704934 Phase 3 Trastuzumab deruxtecan;Ramucirumab;Paclitaxel
26 RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV Recruiting NCT04375605 Phase 3 5-Fluorouracil;Calcium folinate;Oxaliplatin;Docetaxel;Oxaliplatin during radiotherapy;5-Fluorouracil during radiotherapy
27 A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression Recruiting NCT05052801 Phase 3 Bemarituzumab;mFOLFOX6;Placebo
28 Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO Recruiting NCT04447352 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Cisplatin
29 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression Recruiting NCT05111626 Phase 3 Bemarituzumab;Nivolumab;mFOLFOX6
30 A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma Recruiting NCT05008783 Phase 3 AK104;Placebo
31 A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib Active, not recruiting NCT00680901 Phase 3 Lapatinib;Placebo;Capecitabine;Oxaliplatin
32 A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106) Active, not recruiting NCT04675983 Phase 3 Sintilimab;Ramucirumab;Cisplatin;5-fluorouracil;Oxaliplatin;Capecitabine
33 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Active, not recruiting NCT03777657 Phase 3 Tislelizumab;Placebo;Cisplatin;Oxaliplatin;Capecitabine;5-FU
34 A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811) Active, not recruiting NCT03615326 Phase 3 Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
35 A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) Active, not recruiting NCT04499924 Phase 2, Phase 3 tucatinib;trastuzumab;ramucirumab;paclitaxel
36 A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma Active, not recruiting NCT03802591 Phase 3 CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
37 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
38 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Terminated NCT03019588 Phase 3 Paclitaxel
39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT02137343 Phase 3 Rilotumumab;Placebo;Cisplatin;Capecitabine
40 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma Terminated NCT01697072 Phase 3 Rilotumumab;Epirubicin;Cisplatin;Capecitabine
41 A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction Terminated NCT01641939 Phase 2, Phase 3 Taxane;trastuzumab emtansine
42 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Unknown status NCT04555304 Phase 2 KH903 + Paclitaxel;Placebo + Paclitaxel
43 Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis Unknown status NCT02589496 Phase 2 pembrolizumab
44 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
45 Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT02525237 Phase 2 Apatinib;S-1
46 A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT03219593 Phase 2 Apatinib mesylate tablets
47 Safety and Efficacy Evaluation of Capecitabine, Cisplatin, and Herzuma Combination Chemotherapy for the First Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients. Unknown status NCT03588533 Phase 2 Trastuzumab;Capecitabine;Cisplatin
48 Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma Unknown status NCT03950271 Phase 2 SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
49 A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
50 A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ,III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction Unknown status NCT03349866 Phase 2 apatinib;Capecitabine;Oxaliplatin

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

Organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

MalaCards : Breast, Pancreas, T Cells, Lung, Liver, Endothelial, Lymph Node

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 347)
# Title Authors PMID Year
1
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. 62
36241842 2022
2
Esophageal Grape-Like Lesion in a 41-Year-Old Man With a History of Gastroesophageal Junction Adenocarcinoma. 62
35728687 2022
3
Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. 62
36125657 2022
4
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort. 62
36394147 2022
5
Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study. 62
35880759 2022
6
[Clinical characteristics of digestive system cancers metastatic to the heart]. 62
36380673 2022
7
Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. 62
36384091 2022
8
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. 62
35304622 2022
9
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis. 62
36352476 2022
10
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. 62
36379002 2022
11
Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment? 62
36042124 2022
12
Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma. 62
36212240 2022
13
Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma? 62
36114920 2022
14
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. 62
35778636 2022
15
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. 62
35704113 2022
16
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST. 62
36143086 2022
17
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives. 62
36175985 2022
18
Tandem mass tagging combined with liquid chromatography-tandem mass spectrometry technique to detect protein markers in gastroesophageal junction adenocarcinoma. 62
35840340 2022
19
Preoperative radiotherapy affects the prognosis of patients with stage T1-3N0-1M0 gastroesophageal junction adenocarcinoma. 62
35961911 2022
20
Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection. 62
36160743 2022
21
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. 62
35657979 2022
22
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. 62
35852104 2022
23
Correction to: Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC). 62
35523994 2022
24
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. 62
35834132 2022
25
Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. 62
35902798 2022
26
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. 62
35833783 2022
27
Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States. 62
35837150 2022
28
Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. 62
35837173 2022
29
Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC). 62
35430699 2022
30
Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma. 62
35695051 2022
31
Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study. 62
35813347 2022
32
Proportion of Early-Onset Gastric and Esophagus Cancers Has Changed Over Time With Disproportionate Impact on Black and Hispanic Patients. 62
35544654 2022
33
The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma. 62
35634180 2022
34
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. 62
35617520 2022
35
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. 62
35579894 2022
36
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. 62
35380714 2022
37
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. 62
35296556 2022
38
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. 62
33900864 2022
39
Esophageal Adenocarcinoma in an Active Duty Sailor: A Case Report. 62
35355077 2022
40
Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma. 62
34677650 2022
41
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. 62
35267477 2022
42
Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. 62
35280426 2022
43
A case of severe vasculitis after FLOT chemotherapy in a patient with metastatic gastric cancer who received multiple line chemotherapy. 62
35044279 2022
44
Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries. 62
34718236 2022
45
Metastatic esophageal cancer presenting as bladder mass, a case report. 62
34849343 2022
46
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. 62
35531474 2022
47
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. 62
34992093 2022
48
Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma. 62
36330490 2022
49
New Horizons for Personalised Treatment in Gastroesophageal Cancer. 62
35054006 2022
50
Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II-III gastroesophageal junction adenocarcinoma: A large population-based cohort study. 62
36338703 2022

Variations for Gastroesophageal Junction Adenocarcinoma

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFD VEGFC VEGFB VEGFA TP53 MET
2
Show member pathways
13.87 VEGFD VEGFC VEGFB TP53 MET KDR
3
Show member pathways
13.83 VEGFA TP53 PDCD1 MET KDR FGFR2
4 13.83 VEGFD VEGFC VEGFB VEGFA TP53 MET
5
Show member pathways
13.76 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6
Show member pathways
13.68 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
7
Show member pathways
13.64 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
8
Show member pathways
13.58 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
9
Show member pathways
13.52 VEGFA TP53 MET KDR FGFR2 ERBB3
10
Show member pathways
13.47 VEGFD VEGFC VEGFB TP53 MET KDR
11
Show member pathways
13.42 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
12
Show member pathways
13.39 EGFR ERBB2 FGFR2 FLT1 KDR MET
13
Show member pathways
13.34 VEGFD VEGFC VEGFB VEGFA MET KDR
14
Show member pathways
13.17 VEGFD VEGFC VEGFB TP53 MET KDR
15
Show member pathways
13.15 VEGFD VEGFC VEGFB MET KDR FLT1
16
Show member pathways
13.11 TP53 MET FGFR2 ERBB3 ERBB2 EGFR
17
Show member pathways
13.06 MET KDR FLT1 FGFR2 ERBB3 ERBB2
18
Show member pathways
13 VEGFD VEGFC VEGFB VEGFA TP53 MET
19
Show member pathways
12.8 VEGFA TP53 KDR FGFR2 ERBB2 EGFR
20
Show member pathways
12.8 VEGFD VEGFC VEGFB MET KDR FLT1
21
Show member pathways
12.73 MET FGFR2 ERBB3 ERBB2 EGFR
22
Show member pathways
12.72 VEGFD VEGFC VEGFB TP53 MET KDR
23
Show member pathways
12.56 VEGFD VEGFC VEGFB VEGFA KDR FLT1
24
Show member pathways
12.53 TP53 ERBB3 ERBB2 EGFR
25
Show member pathways
12.53 TP53 MET KDR FLT1 FGFR2 ERBB3
26 12.51 CD274 EGFR FGFR2 FLT1 KDR MET
27
Show member pathways
12.48 TP53 MET ERBB3 ERBB2
28
Show member pathways
12.48 TP53 FGFR2 ERBB2 EGFR
29
Show member pathways
12.45 FLT1 KDR VEGFA VEGFB VEGFC VEGFD
30
Show member pathways
12.44 EGFR FGFR2 FLT1 KDR MET VEGFA
31
Show member pathways
12.43 CD274 CTLA4 PDCD1 PDCD1LG2
32
Show member pathways
12.42 VEGFD VEGFC VEGFB MET KDR FLT1
33 12.36 MET KDR FLT1 FGFR2 EGFR
34
Show member pathways
12.32 EGFR FGFR2 FLT1 KDR VEGFA VEGFB
35
Show member pathways
12.31 TP53 MET KDR FLT1 FGFR2 ERBB3
36 12.27 VEGFD VEGFC VEGFB VEGFA MET KDR
37 12.12 VEGFD VEGFC VEGFB VEGFA MET KDR
38 12.11 TP53 MET KDR FLT1 FGFR2 ERBB3
39
Show member pathways
12.1 TP53 ERBB3 ERBB2 EGFR
40
Show member pathways
12.02 MET KDR FLT1 FGFR2 EGFR
41 12 VEGFC VEGFB KDR FLT1 FGFR2
42 11.93 EGFR FLT1 KDR VEGFA
43 11.9 VEGFA TP53 FGFR2 ERBB2 EGFR
44
Show member pathways
11.88 VEGFA ERBB2 EGFR
45 11.86 VEGFD VEGFC VEGFB FGFR2 ERBB3 ERBB2
46
Show member pathways
11.82 PDCD1LG2 PDCD1 CD274
47 11.79 VEGFA TP53 FGFR2
48 11.78 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
49 11.76 VEGFA TP53 KDR FLT1
50 11.73 VEGFA KDR FGFR2 EGFR

GO Terms for Gastroesophageal Junction Adenocarcinoma

Cellular components related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.97 CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
2 membrane GO:0016020 10.97 CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
3 plasma membrane GO:0005887 10.45 CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
4 plasma membrane GO:0005886 10.45 CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
5 extracellular region GO:0005576 10.43 VEGFD VEGFC VEGFB VEGFA PDCD1LG2 MET
6 platelet alpha granule lumen GO:0031093 9.92 VEGFD VEGFC VEGFB VEGFA
7 basal plasma membrane GO:0009925 9.86 EGFR ERBB2 ERBB3 MET
8 ERBB3:ERBB2 complex GO:0038143 9.71 ERBB3 ERBB2
9 receptor complex GO:0043235 9.47 MET KDR FLT1 FGFR2 ERBB3 ERBB2
10 plasma membrane region GO:0098590 9.33 ERBB3 ERBB2 EGFR
11 obsolete spanning component of plasma membrane GO:0044214 9.13 ERBB3 ERBB2 EGFR

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 10.37 CD274 EGFR ERBB2 MET PDCD1LG2
2 positive regulation of protein phosphorylation GO:0001934 10.37 VEGFD VEGFC VEGFB VEGFA KDR ERBB2
3 positive regulation of cell population proliferation GO:0008284 10.35 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
4 negative regulation of apoptotic process GO:0043066 10.34 VEGFB VEGFA TP53 KDR ERBB3 ERBB2
5 positive regulation of cell migration GO:0030335 10.31 VEGFC VEGFA KDR FLT1 EGFR CD274
6 positive regulation of angiogenesis GO:0045766 10.31 FLT1 KDR VEGFA VEGFB VEGFC VEGFD
7 protein autophosphorylation GO:0046777 10.3 EGFR ERBB2 FGFR2 FLT1 KDR
8 response to hypoxia GO:0001666 10.28 VEGFD VEGFC VEGFB VEGFA
9 protein phosphorylation GO:0006468 10.28 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
10 angiogenesis GO:0001525 10.28 VEGFD VEGFC VEGFA KDR FLT1 FGFR2
11 peptidyl-tyrosine phosphorylation GO:0018108 10.27 MET KDR FLT1 FGFR2 ERBB3 ERBB2
12 positive regulation of endothelial cell proliferation GO:0001938 10.25 VEGFD VEGFC VEGFB VEGFA KDR
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.25 MET KDR FLT1 FGFR2 ERBB3 ERBB2
14 positive regulation of MAPK cascade GO:0043410 10.24 ERBB2 FGFR2 FLT1 KDR VEGFA
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.23 VEGFB VEGFA KDR FGFR2 EGFR
16 positive regulation of MAP kinase activity GO:0043406 10.21 VEGFA FLT1 ERBB2 EGFR
17 positive regulation of cell division GO:0051781 10.21 FGFR2 VEGFA VEGFB VEGFC VEGFD
18 positive chemotaxis GO:0050918 10.18 MET VEGFA VEGFB VEGFC VEGFD
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.16 VEGFA KDR FLT1 ERBB3
20 sprouting angiogenesis GO:0002040 10.16 VEGFA VEGFB VEGFC VEGFD
21 negative regulation of T cell proliferation GO:0042130 10.15 PDCD1LG2 CTLA4 CD274
22 positive regulation of blood vessel endothelial cell migration GO:0043536 10.14 VEGFC VEGFA KDR
23 positive regulation of protein kinase B signaling GO:0051897 10.13 VEGFB VEGFA MET EGFR
24 positive regulation of epithelial cell proliferation GO:0050679 10.13 EGFR ERBB2 FGFR2 KDR VEGFA VEGFC
25 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.12 VEGFA KDR FLT1
26 phosphorylation GO:0016310 10.12 MET KDR FLT1 FGFR2 ERBB3 ERBB2
27 regulation of ERK1 and ERK2 cascade GO:0070372 10.1 FGFR2 ERBB2 EGFR
28 induction of positive chemotaxis GO:0050930 10.1 VEGFD VEGFC VEGFB VEGFA
29 positive regulation of kinase activity GO:0033674 10.1 MET KDR FLT1 FGFR2 ERBB3 ERBB2
30 vascular wound healing GO:0061042 9.99 VEGFA KDR
31 ERBB2-EGFR signaling pathway GO:0038134 9.98 ERBB2 EGFR
32 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.96 KDR VEGFA
33 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.96 KDR VEGFA
34 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.96 TP53 VEGFA
35 ERBB2-ERBB3 signaling pathway GO:0038133 9.95 ERBB3 ERBB2
36 positive regulation of phosphorylation GO:0042327 9.94 EGFR KDR VEGFA
37 positive regulation of mast cell chemotaxis GO:0060754 9.92 VEGFA VEGFB VEGFC VEGFD
38 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.73 VEGFD VEGFC VEGFB VEGFA KDR FLT1
39 multicellular organism development GO:0007275 9.7 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
40 positive regulation of miRNA maturation GO:1903800 9.67 TP53 EGFR
41 vascular endothelial growth factor signaling pathway GO:0038084 9.4 VEGFD VEGFC VEGFB VEGFA KDR FLT1

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.51 VEGFD VEGFB VEGFA TP53 MET KDR
2 protein phosphatase binding GO:0019903 10.08 TP53 MET ERBB2 EGFR
3 kinase activity GO:0016301 9.95 MET KDR FLT1 FGFR2 ERBB3 ERBB2
4 growth factor binding GO:0019838 9.92 KDR FLT1 ERBB3 ERBB2
5 protein kinase activity GO:0004672 9.91 EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6 chemoattractant activity GO:0042056 9.86 VEGFD VEGFC VEGFB VEGFA
7 vascular endothelial growth factor receptor activity GO:0005021 9.84 KDR FLT1
8 ErbB-3 class receptor binding GO:0043125 9.83 ERBB3 ERBB2
9 receptor ligand activity GO:0048018 9.83 VEGFD VEGFC VEGFB VEGFA
10 vascular endothelial growth factor receptor 1 binding GO:0043183 9.8 VEGFA VEGFB
11 protein tyrosine kinase activity GO:0004713 9.77 MET KDR FLT1 FGFR2 ERBB3 ERBB2
12 vascular endothelial growth factor receptor 3 binding GO:0043185 9.76 VEGFD VEGFC
13 vascular endothelial growth factor receptor binding GO:0005172 9.76 VEGFA VEGFB VEGFC VEGFD
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.44 MET KDR FLT1 FGFR2 ERBB3 ERBB2

Sources for Gastroesophageal Junction Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....